National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Olaparib (Lynparza®) as monotherapy for the maintenance treatment of adult patients with BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. This is a sub-group of the entire licensed population.

NCPE Assessment Process Complete
Rapid Review commissioned 23/07/2019
Rapid Review completed 06/08/2019
Rapid Review Outcome A full HTA is not recommended. The NCPE recommends that olaparib not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.